Quanterix Corporation enters its Q1 2026 earnings report — released after the close on May 6 — with shorts sitting at a meaningful share of the float, options traders more cautious than usual, and analyst targets that have been cut sharply over the past month.
The positioning story is genuinely two-sided. Short interest runs at 9.1% of the free float, a level that has barely moved over the past month, edging up just 1.9% over 30 days while drifting fractionally lower this week to roughly 4.24 million shares. The borrow market is loose — the ORTEX short score of 55.8 sits in the mid-range, and lending availability is far from exhausted, well below the 52-week peak utilisation of 57%. At the same time, cost to borrow has jumped 243% over the past week to 0.49% APR. That sounds dramatic, but the absolute level remains low and the history shows volatile day-to-day swings, so the direction of travel is worth watching rather than the number alone. Borrow is not scarce here; the spike looks more like noise in a normally quiet lending market than a sign of mounting squeeze pressure.
Options traders have grown more defensive into the print. The put/call ratio has climbed to 0.17, nearly 1.7 standard deviations above its 20-day average of 0.12 — a relatively elevated reading for a stock that typically sees almost entirely call-dominated flow. The 52-week high on the PCR is 0.46, so there's headroom before this becomes an extreme, but the directional shift over the past two weeks is clear. Traders who had been almost entirely positioned for upside have added some downside protection.
The Street's message has been consistent and grim. The most recent analyst action, from Canaccord Genuity on April 20, halved the price target from $8.00 to $4.00 while keeping a Hold rating. That followed a downgrade from Buy in August 2025 and a series of target cuts stretching back through 2025. A Scotiabank Sector Outperform rating with a target of $18.00 remains on the books, but that was set in March 2025 — a time when the stock was trading at multiples of its current $3.30 — and should be treated as stale context rather than active guidance. The mean target across the coverage group works out to roughly $5.33, implying meaningful upside on paper, but the trajectory of that number has been sharply downward. Factor scores add little comfort: EPS momentum ranks in the 36th percentile, the dividend score at the 32nd, and the short-score rank at the 28th. The company is loss-making on every P&L metric — EPS of -$2.08, EBITDA of -$45.5M — with net debt of -$64.5M indicating cash remains on hand, but operating cash burn of -$12.9M per year.
On the institutional side, Columbia Management Investment Advisers added 752,000 shares to reach 10.6% of the company, and William Blair added 731,000 to reach 4.3%, both as of the Q1 close. Those are meaningful builds. BlackRock also added a modest 263,000 shares. On the other side, Easterly cut its position by 635,000 shares and Millennium trimmed by 807,000. The net picture is a handful of longer-term holders adding while quant and event-driven names reduce. Insider activity tells a quieter story — the COO and CFO made small sales through April to cover awards, with the total 90-day net value barely above $5,600 — no directional signal there.
The last earnings print is instructive. Following the March 2, 2026 Q4 results, the stock fell 10.4% the next day and shed a further 22.1% over the following five days. Tonight's Q1 report arrived after the market close with EPS of -$0.37, beating the -$0.45 estimate, though revenue at $36.4M came in just under the $37.2M consensus. Full-year 2026 sales guidance was affirmed at $169M–$174M. The Lucent Diagnostics collaboration with Tempus to integrate blood-based Alzheimer's biomarker testing into clinical workflows, announced the same day, adds a commercial narrative to the print. How the market weighs a revenue miss and guidance hold against that partnership announcement — set against a backdrop of 9% short interest and a stock down 13% over the past month — is the question that will define the next session's price action.
See the live data behind this article on ORTEX.
Open QTRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
